Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 575

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Insulin-Like Growth Factor 1 and Prostate Cancer Risk: A Population-Based, Case-Control Study

Wolk, A., Mantzoros, C. S., Andersson, S.-O., Bergstrom, R., Signorello, L. B., Lagiou, P., Adami, H.-O., Trichopoulos, D.·1998·JNCI Journal of the National Cancer Institute

Abstract

BACKGROUND: Recent epidemiologic investigations have suggested an association between increased blood levels of insulin-like growth factor 1 (IGF-1) and increased risk of prostate cancer. Our goal was to determine whether an association exists between serum levels of IGF-1 and one of its binding proteins, insulin-like growth factor-binding protein 3 (IGFBP-3), and prostate cancer risk. METHODS: An immunoradiometric assay was used to quantify IGF-1 levels and IGFBP-3 levels in serum samples as part of a population-based, case-control study in Sweden. The study population comprised 210 patients with newly diagnosed, untreated prostate cancer and 224 frequency-matched control subjects. Data were analyzed by use of unconditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Reported P values are two-sided. RESULTS: The mean serum IGF-1 level for case patients (158.4 ng/mL) was significantly higher than that for control subjects (147.4 ng/mL) (P = .02); corresponding mean serum IGFBP-3 levels were not significantly different between case patients (2668 ng/mL) and control subjects (2518 ng/mL) (P =.09). We found a moderately strong and statistically significant (P = .04) positive association between serum levels of IGF-1 levels and risk of prostate cancer (OR = 1.51; 95% CI = 1.0-2.26 per 100 ng/mL increment); the association was particularly strong for men younger than 70 years of age (OR = 2.93; 95% CI = 1.43-5.97). No association was found between serum IGF-1 levels and disease stage. Serum IGFBP-3 levels were not significantly associated with increased risk of disease, and adjustment for IGFBP-3 had little effect on the association between IGF-1 levels and risk of prostate cancer. CONCLUSION: Elevated serum IGF-1 levels may be an important predictor of risk for prostate cancer. However, our results do not support an important role for serum IGFBP-3 as a predictor of risk for this disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/90.12.911

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 575

Metadata

Authors
Wolk, A., Mantzoros, C. S., Andersson, S.-O., Bergstrom, R., Signorello, L. B., Lagiou, P., Adami, H.-O., & Trichopoulos, D.
Venue
JNCI Journal of the National Cancer Institute
Published
1998-06-17
Volume
90
Issue
12
Pages
911-915
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2159318197
Cited by
575
References
24
FWCI
32.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin-Like Growth Factor 1 and Prostate Cancer Risk: A Population-Based, Case-Control Study. https://app.cochat.ai/papers/10.1093/jnci/90.12.911
The paper
Wolk, A., Mantzoros, C. S., Andersson, S.-O., Bergstrom, R., Signorello, L. B., Lagiou, P., Adami, H.-O., & Trichopoulos, D. (1998). Insulin-Like Growth Factor 1 and Prostate Cancer Risk: A Population-Based, Case-Control Study. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/90.12.911

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.